EICHOR
● Completed
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
Condition: Advanced Non-Small Cell Lung Cancer · Sponsor: Merck Sharp & Dohme LLC
About this study
This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile \[GEP\] and tumor mutational burden \[TMB\]) will be randomized to receive pembrolizumab in combination with quavonlimab (MK-1308), favezelimab (MK-4280), or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either quavonlimab, favezelimab, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (81)
| Arizona Oncology Associates, PC- HAL ( Site 8001) | Tempe, Arizona, United States | — |
| University of California Davis Comprehensive Cancer Center ( Site 0137) | Sacramento, California, United States | — |
| University of California San Francisco ( Site 0111) | San Francisco, California, United States | — |
| UCLA Hematology/Oncology -Santa Monica ( Site 0108) | Santa Monica, California, United States | — |
| Yale University School of Medicine ( Site 0100) | New Haven, Connecticut, United States | — |
| Mayo Clinic Florida ( Site 0115) | Jacksonville, Florida, United States | — |
| University of Maryland ( Site 0136) | Baltimore, Maryland, United States | — |
| Mayo Clinic Rochester - St. Mary's Hospital ( Site 0117) | Rochester, Minnesota, United States | — |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0112) | Hackensack, New Jersey, United States | — |
| Memorial Sloan Kettering Cancer Center ( Site 0113) | New York, New York, United States | — |
| Weill Cornell Medical College ( Site 0138) | New York, New York, United States | — |
| Oncology Hematology Care ( Site 8005) | Cincinnati, Ohio, United States | — |
+ 69 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03516981